Related Experiment Video
Updated: Aug 6, 2026
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
Dual REmission in moderate-to-severe AsthMa and Nasal Polyps: a multicentric observational Phase IV real-life study
Francesco Menzella1,2, Eugenio De Corso3, Marco Caminati4
1Pulmonology Unit, S. Valentino Hospital, AULSS2 Marca Trevigiana, Montebelluna, Italy.
Background:
Achieving simultaneous 'dual remission' in both upper and lower airways is the clinical goal for comorbid asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). This multicentric observational study evaluated the 24-month real-world effectiveness of dupilumab in reaching these stringent endpoints.
Methods:
A retrospective study of 205 adult patients was conducted. Remission was defined by SANI criteria for asthma and modified EPOS/EUFOREA-DUPIREAL benchmarks for CRSwNP. Complete recovery required dual remission plus normosmia restoration.
Results:
At 24 months, 77.4% of patients with severe asthma achieved CRSwNP remission, significantly higher than the 61.8% in the moderate asthma group (p = 0.0309). Dual remission was reached by 22.9% of the overall cohort. High baseline FeNO (≥50 ppb) was the strongest predictor for dual remission (34.5%) and normosmia restoration (19.2%). Prior surgery did not hinder long-term outcomes; surgical patients achieved complete recovery significantly faster at 12 months (16.7% vs. 3%, p = 0.0115). A higher surgical burden positively predicted olfactory restoration (OR = 4.0 per revision, p = 0.045).
Conclusions:
Dupilumab is highly effective over the long term, exhibiting a structural 'catch-up" effect. While high baseline Type 2 biomarkers and surgical history are positive prognostic indicators, the persistent "clinical-functional gap' suggests earlier intervention is critical to prevent irreversible neuroepithelial damage.
Clinical Trial Registration:
www.clinicaltrials.gov identifier is NCT07574294.
Related Concept Videos
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
01:24Asthma-III: Symptoms and Complications
Classification of Asthma
01:26Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
01:30Asthma-IV: Nursing Management
First, in...
01:30Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:20Antiasthma Drugs: Muscarinic Receptor Antagonists
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...